Pathstone Family Office’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $3.94M | Buy |
52,159
+37,417
| +254% | +$2.88M | 0.03% | 321 |
|
|
2023
Q2 | $1.1M | Sell |
14,742
-47
| -0.3% | -$3.75K | 0.02% | 452 |
|
|
2023
Q1 | $1.21M | Sell |
14,789
-50,305
| -77% | -$4.17M | 0.02% | 396 |
|
|
2022
Q4 | $4.18M | Buy |
65,094
+23,256
| +56% | +$1.84M | 0.04% | 309 |
|
|
2022
Q3 | $2.63M | Buy |
41,838
+31,864
| +319% | +$2.01M | 0.02% | 349 |
|
|
2022
Q2 | $617K | Buy |
9,974
+5,207
| +109% | +$322K | 0.01% | 495 |
|
|
2022
Q1 | $308K | Sell |
4,767
-973
| -17% | -$62.2K | 0.01% | 738 |
|
|
2021
Q4 | $417K | Buy |
5,740
+765
| +15% | +$52.7K | 0.01% | 609 |
|
|
2021
Q3 | $347K | Sell |
4,975
-110
| -2% | -$7.73K | 0.01% | 625 |
|
|
2021
Q2 | $350K | Sell |
5,085
-202
| -4% | -$13.5K | 0.01% | 589 |
|
|
2021
Q1 | $341K | Buy |
5,287
+2,513
| +91% | +$162K | 0.01% | 448 |
|
|
2020
Q4 | $162K | Buy |
2,774
+2,622
| +1,725% | +$158K | 0.01% | 292 |
|
|
2020
Q3 | $9K | Buy |
152
+145
| +2,071% | +$10.1K | ﹤0.01% | 615 |
|
|
2020
Q2 | $1K | Hold |
7
| – | – | ﹤0.01% | 670 |
|
|
2020
Q1 | $1K | Buy |
+7
| New | +$484 | ﹤0.01% | 718 |
|
|
2019
Q4 | – | Sell |
-68
| Closed | -$4K | – | 504 |
|
|
2019
Q3 | $4K | Buy |
+68
| New | +$4.45K | ﹤0.01% | 546 |
|
|
2019
Q2 | – | Sell |
-47
| Closed | -$3K | – | 729 |
|
|
2019
Q1 | $3K | Buy |
+47
| New | +$3.12K | ﹤0.01% | 685 |
|
|
2018
Q4 | – | Sell |
-40
| Closed | -$3K | – | 540 |
|
|
2018
Q3 | $3K | Buy |
+40
| New | +$3.02K | ﹤0.01% | 204 |
|
|
2018
Q1 | – | Sell |
-36
| Closed | -$3K | – | 376 |
|
|
2017
Q4 | $3K | Sell |
36
-125
| -78% | -$9.49K | ﹤0.01% | 120 |
|
|
2017
Q3 | $13K | Sell |
161
-5,500
| -97% | -$421K | 0.01% | 122 |
|
|
2017
Q2 | $401K | Sell |
5,661
-59,064
| -91% | -$3.93M | 0.17% | 57 |
|
|
2017
Q1 | $4.45M | Sell |
64,725
-2,193
| -3% | -$154K | 2.45% | 6 |
|
|
2016
Q4 | $5.57M | Buy |
66,918
+4,746
| +8% | +$353K | 3.54% | 4 |
|
|
2016
Q3 | $5.37M | Buy |
62,172
+61,694
| +12,907% | +$5.01M | 5.53% | 4 |
|
|
2016
Q2 | $40K | Sell |
478
-60,262
| -99% | -$5.35M | 0.04% | 62 |
|
|
2016
Q1 | $5.58M | Buy |
60,740
+60,588
| +39,861% | +$5.46M | 11.31% | 3 |
|
|
2015
Q4 | $15K | Sell |
152
-59,856
| -100% | -$6.23M | 0.07% | 38 |
|
|
2015
Q3 | $5.89M | Buy |
60,008
+59,857
| +39,640% | +$6.65M | 15.89% | 2 |
|
|
2015
Q2 | $18K | Sell |
151
-59,399
| -100% | -$6.49M | 0.03% | 59 |
|
|
2015
Q1 | $5.84M | Buy |
59,550
+50
| +0.1% | +$5.08K | 9.41% | 3 |
|
|
2014
Q4 | $5.61M | Hold |
59,500
| – | – | 19.09% | 2 |
|
|
2014
Q3 | $6.33M | Buy |
59,500
+59,400
| +59,400% | +$5.82M | 19.65% | 2 |
|
|
2014
Q2 | $8K | Sell |
100
-100
| -50% | -$7.78K | 0.02% | 106 |
|
|
2014
Q1 | $14K | Sell |
200
-60,560
| -100% | -$4.75M | 0.04% | 80 |
|
|
2013
Q4 | $4.56M | Hold |
60,760
| – | – | 9.92% | 3 |
|
|
2013
Q3 | $3.82M | Sell |
60,760
-1,100
| -2% | -$65.7K | 16.54% | 1 |
|
|
2013
Q2 | $3.17M | Buy |
+61,860
| New | +$3.22M | 3.68% | 2 |
|
Other funds holding GILD
Pathstone Family Office's GILD Position: Q3 2023 in Review
Pathstone Family Office increased its Gilead Sciences (GILD) stake by 254% in Q3 2023, buying an estimated $2.88M and bringing the position to 52,159 shares worth $3.94M. The position accounts for 0.03% of the portfolio, ranked #321.
Pathstone Family Office first reported a position in GILD in Q2 2013 and has held it in 37 quarters since. The position peaked at $6.33M in Q3 2014. 1,681 funds tracked by Wall St. Rank hold GILD as of Q3 2023.
- Pathstone Family Office held 52,159 shares of Gilead Sciences worth $3.94M as of Q3 2023.
- Pathstone Family Office bought 37,417 Gilead Sciences shares in Q3 2023, an estimated $2.88M.
- Gilead Sciences made up 0.03% of Pathstone Family Office's portfolio in Q3 2023, its #321 holding.
- Pathstone Family Office first reported a position in Gilead Sciences in Q2 2013 and has held it in 37 quarters since.
- Pathstone Family Office's Gilead Sciences position peaked at $6.33M in Q3 2014.
- 1,681 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.
Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.